Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 18;1(1):28-35.
doi: 10.2991/chi.d.190316.002. eCollection 2019 Mar.

Fecal Microbiota Transplantation for Treatment of Acute Graft- versus-Host Disease

Roni Shouval  1   2 , Mika Geva  1 , Arnon Nagler  1 , Ilan Youngster  3
Affiliations
Review

Fecal Microbiota Transplantation for Treatment of Acute Graft- versus-Host Disease

Roni Shouval et al. Clin Hematol Int. .

Abstract

The growing understanding of the bidirectional relationship between the gastrointestinal (GI) microbiome and the immune system has opened up new avenues for treatment of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is the transfer of stool from a donor to a recipient who harbors a perturbed GI microbiome resulting in disease. We review the rationale for performing FMT for the treatment of acute GVHD, and summarize data on the safety and efficacy of the procedure among allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Overall, FMT is a promising strategy in treating and preventing HSCT-related complications. However, caution should be exerted as HSCT recipients are highly immunosuppressed and unanticipated infectious adverse events may appear with the increasing application of FMT.

Keywords: Fecal microbiota transplantation; Graft-versus-host disease; Hematopoietic stem cell transplantation; Microbiome.

PubMed Disclaimer

Conflict of interest statement

Authors have not relevant competing interests to disclose. Role of Funding Source: The funding source had no role in this work.

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26. doi: 10.1056/NEJMra052638. - DOI - PubMed
    1. Jagasia M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307. doi: 10.1182/blood-2011-06-364265. - DOI - PMC - PubMed
    1. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–79. doi: 10.1056/NEJMra1609337. - DOI - PMC - PubMed
    1. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014;124(3):363–73. doi: 10.1182/blood-2014-01-514786. - DOI - PMC - PubMed
    1. Ferrara JL, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61. doi: 10.1016/S0140-6736(09)60237-3. - DOI - PMC - PubMed

LinkOut - more resources